|Day Low/High||175.71 / 181.22|
|52 Wk Low/High||123.73 / 182.47|
Companies have lots of repatriated cash to use on purchases.
As Wall Street prepares for another rough day, these are the business stories you must know.
I think M&A activity will pick up markedly going forward across the industry.
A look at three names to consider in the biotech and biopharma space.
Data and industry conferences will likely be catalysts for shares in the space.
Better-than-expected earnings will help soothe market jitters in the second quarter.
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
There are a variety of players that should be active in the M&A space next year.
The Philly Fed manufacturing index was strong in May, rising 38.8 vs. 22.0 in April. Jobless claims fell to 232,000 from 236,000 last week. Walmart beat earnings estimates by four cents, earning $1.00 per share vs. the consensus estimate of 96 cents...
BioCryst's Hereditary angioedema drug-trial results not compelling.
The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.
Given the biotech's growth prospects and pipeline assets, its shares seem greatly undervalued.
U.S. stocks rose Wednesday, building on Tuesday's gains, as Brexit fears dissipated.
We need some cooperation from China and oil. Please.
Ireland’s Shire has clinched Baxalta with a stock and cash deal worth $32 billion on Monday.
U.S. stocks lost earlier gains to fall into the red after another selloff in crude oil prices pressured the energy sector.
Investors are praying that 2016 starts on an uplifting note.
Leaders of oil producing nations begin gathering in Vienna today for the OPEC meeting.
Good morning, all! Bret Jensen here! I'm happy to be sitting in for Doug Kass once again on the Daily Diary. We'll find out today whether the market can make it three days in a row on the upside, as November has opened with a big rally despite so-so...